SlideShare ist ein Scribd-Unternehmen logo
1 von 8
Visualize the pharma twittersphere



jeudi, 21 janvier 2010
Pfizer leads in terms of followers despite a late start; GSKUS most
           impresssive growth (77% vs 51% on average)

  #
of
Followers




                                                                                                     
2
699




                                                                                                     1
313




                              Avg
Dec
09
                              Avg
Jul
09

                         Source:
www.twi-er.com,
July
13th
and
Dec
31st
2009;
whdotpharma
analysis

jeudi, 21 janvier 2010
Great divide on following policy amongst pharma twitter accounts –
       question of “social media maturity“?

            #
of
Following




                                                                                                     
600

                                                                                                     392




                              Avg
Dec
09
                              Avg
Jul
09
                         Source:
www.twi-er.com,
July
13th
and
Dec
31st
2009;
whdotpharma
analysis

jeudi, 21 janvier 2010
Great divide also on activity – indicator for degree of engagement?

        #
of
Updates




                                                                                                     
255


                                                                                                     119




                              Avg
Dec
09
                              Avg
Jul
09

                         Source:
www.twi-er.com,
July
13th
and
Dec
31st
2009;
whdotpharma
analysis

jeudi, 21 janvier 2010
Boehringer and JNJ track above average in terms of engagement

     #
of
Following




                                                     The twitter engagement
                                                     quardrant: above
                                                     average followers,
                                                     following and updates!
                 Average
following:
392




                                  Average
Updates:
119                                                                #
of
Updates
                                                                                       Bubble
size
=
#
of
followers
                         Source:
www.twi-er.com,
July
13th
and
Dec
31st
2009;
whdotpharma
analysis

jeudi, 21 janvier 2010
... Roche and AstraZeneca moving into the “engagement“ quardrant

      #
of
Following




                             @Pfizer_news



                          Avrg
following:
600

                         @genentechnews




                                            Avrg
Updates:
255                                                                #
of
Updates
                                                                                         Avrg
Bubble
size
=
#
of
followers
                           Source:
www.twi-er.com,
July
13th
and
Dec
31st
2009;
whdotpharma
analysis

jeudi, 21 janvier 2010
26% of Boehringer followers are large accounts (>500 followers) vs. only
              14% for Novartis - less is more?

                                                                                                   Number of    % with >500
                                                                                                   followers    followers


                                                                                                     3 941      15%

                                                                                                     3 865      14%

                                                                                                     3 304      26%

                                                                                                     2 780      20%

                                                                                                     2 574      20%

                                                                                                          Avrg 19%

       Number of followers that
       are followed by




              19% of pharma followers (roughly 3000 accounts) are large accounts (>500 followers).
              The segmentation and profiling of these accounts, will be the basis of Part II of this analysis.


                         Source:
www.twi-er.com,
Dec
31st
2009;
whdotpharma
analysis


jeudi, 21 janvier 2010
Coming to whydotpharma soon:
                         the mapping of the pharma twittersphere!




                                                        Stay tuned!

jeudi, 21 janvier 2010

Weitere ähnliche Inhalte

Andere mochten auch

Andere mochten auch (6)

Eric Hotfelter Resume (1)
Eric Hotfelter Resume (1)Eric Hotfelter Resume (1)
Eric Hotfelter Resume (1)
 
Catedral de lima presentacion-touro
Catedral de lima   presentacion-touroCatedral de lima   presentacion-touro
Catedral de lima presentacion-touro
 
CompTIA A+ ce certificate
CompTIA A+ ce certificateCompTIA A+ ce certificate
CompTIA A+ ce certificate
 
Contro presupuestario dapositivas
Contro presupuestario dapositivasContro presupuestario dapositivas
Contro presupuestario dapositivas
 
TwistedMinds.in
TwistedMinds.inTwistedMinds.in
TwistedMinds.in
 
La carta que tu hijo adolescente no te puede escribir
La carta que tu hijo adolescente no te puede escribirLa carta que tu hijo adolescente no te puede escribir
La carta que tu hijo adolescente no te puede escribir
 

Mehr von Silja Chouquet

Revealing ASCO's social DNA
Revealing ASCO's social DNARevealing ASCO's social DNA
Revealing ASCO's social DNASilja Chouquet
 
Biosimilars discussion on Twitter
Biosimilars discussion on TwitterBiosimilars discussion on Twitter
Biosimilars discussion on TwitterSilja Chouquet
 
Infographic Healthcare Archetypes of conversation
Infographic Healthcare Archetypes of conversation Infographic Healthcare Archetypes of conversation
Infographic Healthcare Archetypes of conversation Silja Chouquet
 
A healthcare case study of ASCO, Novartis and Boehringer conversation on twitter
A healthcare case study of ASCO, Novartis and Boehringer conversation on twitterA healthcare case study of ASCO, Novartis and Boehringer conversation on twitter
A healthcare case study of ASCO, Novartis and Boehringer conversation on twitterSilja Chouquet
 
Three things to know about pharma and twitter
Three things to know about pharma and twitterThree things to know about pharma and twitter
Three things to know about pharma and twitterSilja Chouquet
 
Impact of social media on patient adherence
Impact of social media on patient adherenceImpact of social media on patient adherence
Impact of social media on patient adherenceSilja Chouquet
 
Digipharm workshop2011
Digipharm workshop2011Digipharm workshop2011
Digipharm workshop2011Silja Chouquet
 
20110126smiwhydotpresentation
20110126smiwhydotpresentation20110126smiwhydotpresentation
20110126smiwhydotpresentationSilja Chouquet
 
20100906 hcsmeu digipharmpres
20100906 hcsmeu digipharmpres20100906 hcsmeu digipharmpres
20100906 hcsmeu digipharmpresSilja Chouquet
 
HCSMEU Mission statement
HCSMEU Mission statementHCSMEU Mission statement
HCSMEU Mission statementSilja Chouquet
 
HCSMEU Mission statement
HCSMEU Mission statementHCSMEU Mission statement
HCSMEU Mission statementSilja Chouquet
 
3 3 Globalization Kalyanpur
3 3 Globalization Kalyanpur3 3 Globalization Kalyanpur
3 3 Globalization KalyanpurSilja Chouquet
 
3 2 Globalization Schweitzer
3 2 Globalization Schweitzer3 2 Globalization Schweitzer
3 2 Globalization SchweitzerSilja Chouquet
 
3 1 Globalization Hoogland
3 1 Globalization Hoogland3 1 Globalization Hoogland
3 1 Globalization HooglandSilja Chouquet
 
2 3 Consumer Gritschneder
2 3 Consumer Gritschneder2 3 Consumer Gritschneder
2 3 Consumer GritschnederSilja Chouquet
 

Mehr von Silja Chouquet (20)

Revealing ASCO's social DNA
Revealing ASCO's social DNARevealing ASCO's social DNA
Revealing ASCO's social DNA
 
Biosimilars discussion on Twitter
Biosimilars discussion on TwitterBiosimilars discussion on Twitter
Biosimilars discussion on Twitter
 
Infographic Healthcare Archetypes of conversation
Infographic Healthcare Archetypes of conversation Infographic Healthcare Archetypes of conversation
Infographic Healthcare Archetypes of conversation
 
A healthcare case study of ASCO, Novartis and Boehringer conversation on twitter
A healthcare case study of ASCO, Novartis and Boehringer conversation on twitterA healthcare case study of ASCO, Novartis and Boehringer conversation on twitter
A healthcare case study of ASCO, Novartis and Boehringer conversation on twitter
 
Three things to know about pharma and twitter
Three things to know about pharma and twitterThree things to know about pharma and twitter
Three things to know about pharma and twitter
 
Ideagoras
IdeagorasIdeagoras
Ideagoras
 
Impact of social media on patient adherence
Impact of social media on patient adherenceImpact of social media on patient adherence
Impact of social media on patient adherence
 
Pecha kucha
Pecha kuchaPecha kucha
Pecha kucha
 
Digipharm workshop2011
Digipharm workshop2011Digipharm workshop2011
Digipharm workshop2011
 
20110126smiwhydotpresentation
20110126smiwhydotpresentation20110126smiwhydotpresentation
20110126smiwhydotpresentation
 
20100906 hcsmeu digipharmpres
20100906 hcsmeu digipharmpres20100906 hcsmeu digipharmpres
20100906 hcsmeu digipharmpres
 
Kalkscheune
KalkscheuneKalkscheune
Kalkscheune
 
HCSMEU Mission statement
HCSMEU Mission statementHCSMEU Mission statement
HCSMEU Mission statement
 
Powervote Results
Powervote ResultsPowervote Results
Powervote Results
 
HCSMEU Mission statement
HCSMEU Mission statementHCSMEU Mission statement
HCSMEU Mission statement
 
3 3 Globalization Kalyanpur
3 3 Globalization Kalyanpur3 3 Globalization Kalyanpur
3 3 Globalization Kalyanpur
 
3 2 Globalization Schweitzer
3 2 Globalization Schweitzer3 2 Globalization Schweitzer
3 2 Globalization Schweitzer
 
3 1 Globalization Hoogland
3 1 Globalization Hoogland3 1 Globalization Hoogland
3 1 Globalization Hoogland
 
2 3 Consumer Gritschneder
2 3 Consumer Gritschneder2 3 Consumer Gritschneder
2 3 Consumer Gritschneder
 
Gto Consumer Apelles
Gto Consumer ApellesGto Consumer Apelles
Gto Consumer Apelles
 

Kürzlich hochgeladen

Using IESVE for Loads, Sizing and Heat Pump Modeling to Achieve Decarbonization
Using IESVE for Loads, Sizing and Heat Pump Modeling to Achieve DecarbonizationUsing IESVE for Loads, Sizing and Heat Pump Modeling to Achieve Decarbonization
Using IESVE for Loads, Sizing and Heat Pump Modeling to Achieve DecarbonizationIES VE
 
VoIP Service and Marketing using Odoo and Asterisk PBX
VoIP Service and Marketing using Odoo and Asterisk PBXVoIP Service and Marketing using Odoo and Asterisk PBX
VoIP Service and Marketing using Odoo and Asterisk PBXTarek Kalaji
 
NIST Cybersecurity Framework (CSF) 2.0 Workshop
NIST Cybersecurity Framework (CSF) 2.0 WorkshopNIST Cybersecurity Framework (CSF) 2.0 Workshop
NIST Cybersecurity Framework (CSF) 2.0 WorkshopBachir Benyammi
 
Cybersecurity Workshop #1.pptx
Cybersecurity Workshop #1.pptxCybersecurity Workshop #1.pptx
Cybersecurity Workshop #1.pptxGDSC PJATK
 
9 Steps For Building Winning Founding Team
9 Steps For Building Winning Founding Team9 Steps For Building Winning Founding Team
9 Steps For Building Winning Founding TeamAdam Moalla
 
Anypoint Code Builder , Google Pub sub connector and MuleSoft RPA
Anypoint Code Builder , Google Pub sub connector and MuleSoft RPAAnypoint Code Builder , Google Pub sub connector and MuleSoft RPA
Anypoint Code Builder , Google Pub sub connector and MuleSoft RPAshyamraj55
 
OpenShift Commons Paris - Choose Your Own Observability Adventure
OpenShift Commons Paris - Choose Your Own Observability AdventureOpenShift Commons Paris - Choose Your Own Observability Adventure
OpenShift Commons Paris - Choose Your Own Observability AdventureEric D. Schabell
 
KubeConEU24-Monitoring Kubernetes and Cloud Spend with OpenCost
KubeConEU24-Monitoring Kubernetes and Cloud Spend with OpenCostKubeConEU24-Monitoring Kubernetes and Cloud Spend with OpenCost
KubeConEU24-Monitoring Kubernetes and Cloud Spend with OpenCostMatt Ray
 
Empowering Africa's Next Generation: The AI Leadership Blueprint
Empowering Africa's Next Generation: The AI Leadership BlueprintEmpowering Africa's Next Generation: The AI Leadership Blueprint
Empowering Africa's Next Generation: The AI Leadership BlueprintMahmoud Rabie
 
Nanopower In Semiconductor Industry.pdf
Nanopower  In Semiconductor Industry.pdfNanopower  In Semiconductor Industry.pdf
Nanopower In Semiconductor Industry.pdfPedro Manuel
 
COMPUTER 10: Lesson 7 - File Storage and Online Collaboration
COMPUTER 10: Lesson 7 - File Storage and Online CollaborationCOMPUTER 10: Lesson 7 - File Storage and Online Collaboration
COMPUTER 10: Lesson 7 - File Storage and Online Collaborationbruanjhuli
 
UiPath Studio Web workshop series - Day 7
UiPath Studio Web workshop series - Day 7UiPath Studio Web workshop series - Day 7
UiPath Studio Web workshop series - Day 7DianaGray10
 
Secure your environment with UiPath and CyberArk technologies - Session 1
Secure your environment with UiPath and CyberArk technologies - Session 1Secure your environment with UiPath and CyberArk technologies - Session 1
Secure your environment with UiPath and CyberArk technologies - Session 1DianaGray10
 
Artificial Intelligence & SEO Trends for 2024
Artificial Intelligence & SEO Trends for 2024Artificial Intelligence & SEO Trends for 2024
Artificial Intelligence & SEO Trends for 2024D Cloud Solutions
 
UiPath Platform: The Backend Engine Powering Your Automation - Session 1
UiPath Platform: The Backend Engine Powering Your Automation - Session 1UiPath Platform: The Backend Engine Powering Your Automation - Session 1
UiPath Platform: The Backend Engine Powering Your Automation - Session 1DianaGray10
 
UiPath Studio Web workshop series - Day 8
UiPath Studio Web workshop series - Day 8UiPath Studio Web workshop series - Day 8
UiPath Studio Web workshop series - Day 8DianaGray10
 
Apres-Cyber - The Data Dilemma: Bridging Offensive Operations and Machine Lea...
Apres-Cyber - The Data Dilemma: Bridging Offensive Operations and Machine Lea...Apres-Cyber - The Data Dilemma: Bridging Offensive Operations and Machine Lea...
Apres-Cyber - The Data Dilemma: Bridging Offensive Operations and Machine Lea...Will Schroeder
 
COMPUTER 10 Lesson 8 - Building a Website
COMPUTER 10 Lesson 8 - Building a WebsiteCOMPUTER 10 Lesson 8 - Building a Website
COMPUTER 10 Lesson 8 - Building a Websitedgelyza
 

Kürzlich hochgeladen (20)

Using IESVE for Loads, Sizing and Heat Pump Modeling to Achieve Decarbonization
Using IESVE for Loads, Sizing and Heat Pump Modeling to Achieve DecarbonizationUsing IESVE for Loads, Sizing and Heat Pump Modeling to Achieve Decarbonization
Using IESVE for Loads, Sizing and Heat Pump Modeling to Achieve Decarbonization
 
VoIP Service and Marketing using Odoo and Asterisk PBX
VoIP Service and Marketing using Odoo and Asterisk PBXVoIP Service and Marketing using Odoo and Asterisk PBX
VoIP Service and Marketing using Odoo and Asterisk PBX
 
NIST Cybersecurity Framework (CSF) 2.0 Workshop
NIST Cybersecurity Framework (CSF) 2.0 WorkshopNIST Cybersecurity Framework (CSF) 2.0 Workshop
NIST Cybersecurity Framework (CSF) 2.0 Workshop
 
Cybersecurity Workshop #1.pptx
Cybersecurity Workshop #1.pptxCybersecurity Workshop #1.pptx
Cybersecurity Workshop #1.pptx
 
20230104 - machine vision
20230104 - machine vision20230104 - machine vision
20230104 - machine vision
 
201610817 - edge part1
201610817 - edge part1201610817 - edge part1
201610817 - edge part1
 
9 Steps For Building Winning Founding Team
9 Steps For Building Winning Founding Team9 Steps For Building Winning Founding Team
9 Steps For Building Winning Founding Team
 
Anypoint Code Builder , Google Pub sub connector and MuleSoft RPA
Anypoint Code Builder , Google Pub sub connector and MuleSoft RPAAnypoint Code Builder , Google Pub sub connector and MuleSoft RPA
Anypoint Code Builder , Google Pub sub connector and MuleSoft RPA
 
OpenShift Commons Paris - Choose Your Own Observability Adventure
OpenShift Commons Paris - Choose Your Own Observability AdventureOpenShift Commons Paris - Choose Your Own Observability Adventure
OpenShift Commons Paris - Choose Your Own Observability Adventure
 
KubeConEU24-Monitoring Kubernetes and Cloud Spend with OpenCost
KubeConEU24-Monitoring Kubernetes and Cloud Spend with OpenCostKubeConEU24-Monitoring Kubernetes and Cloud Spend with OpenCost
KubeConEU24-Monitoring Kubernetes and Cloud Spend with OpenCost
 
Empowering Africa's Next Generation: The AI Leadership Blueprint
Empowering Africa's Next Generation: The AI Leadership BlueprintEmpowering Africa's Next Generation: The AI Leadership Blueprint
Empowering Africa's Next Generation: The AI Leadership Blueprint
 
Nanopower In Semiconductor Industry.pdf
Nanopower  In Semiconductor Industry.pdfNanopower  In Semiconductor Industry.pdf
Nanopower In Semiconductor Industry.pdf
 
COMPUTER 10: Lesson 7 - File Storage and Online Collaboration
COMPUTER 10: Lesson 7 - File Storage and Online CollaborationCOMPUTER 10: Lesson 7 - File Storage and Online Collaboration
COMPUTER 10: Lesson 7 - File Storage and Online Collaboration
 
UiPath Studio Web workshop series - Day 7
UiPath Studio Web workshop series - Day 7UiPath Studio Web workshop series - Day 7
UiPath Studio Web workshop series - Day 7
 
Secure your environment with UiPath and CyberArk technologies - Session 1
Secure your environment with UiPath and CyberArk technologies - Session 1Secure your environment with UiPath and CyberArk technologies - Session 1
Secure your environment with UiPath and CyberArk technologies - Session 1
 
Artificial Intelligence & SEO Trends for 2024
Artificial Intelligence & SEO Trends for 2024Artificial Intelligence & SEO Trends for 2024
Artificial Intelligence & SEO Trends for 2024
 
UiPath Platform: The Backend Engine Powering Your Automation - Session 1
UiPath Platform: The Backend Engine Powering Your Automation - Session 1UiPath Platform: The Backend Engine Powering Your Automation - Session 1
UiPath Platform: The Backend Engine Powering Your Automation - Session 1
 
UiPath Studio Web workshop series - Day 8
UiPath Studio Web workshop series - Day 8UiPath Studio Web workshop series - Day 8
UiPath Studio Web workshop series - Day 8
 
Apres-Cyber - The Data Dilemma: Bridging Offensive Operations and Machine Lea...
Apres-Cyber - The Data Dilemma: Bridging Offensive Operations and Machine Lea...Apres-Cyber - The Data Dilemma: Bridging Offensive Operations and Machine Lea...
Apres-Cyber - The Data Dilemma: Bridging Offensive Operations and Machine Lea...
 
COMPUTER 10 Lesson 8 - Building a Website
COMPUTER 10 Lesson 8 - Building a WebsiteCOMPUTER 10 Lesson 8 - Building a Website
COMPUTER 10 Lesson 8 - Building a Website
 

Whydot Pharma Twittersphere Mapping Jan 09

  • 1. Visualize the pharma twittersphere jeudi, 21 janvier 2010
  • 2. Pfizer leads in terms of followers despite a late start; GSKUS most impresssive growth (77% vs 51% on average) #
of
Followers 
2
699 1
313 Avg
Dec
09 Avg
Jul
09 Source:
www.twi-er.com,
July
13th
and
Dec
31st
2009;
whdotpharma
analysis jeudi, 21 janvier 2010
  • 3. Great divide on following policy amongst pharma twitter accounts – question of “social media maturity“? #
of
Following 
600 392 Avg
Dec
09 Avg
Jul
09 Source:
www.twi-er.com,
July
13th
and
Dec
31st
2009;
whdotpharma
analysis jeudi, 21 janvier 2010
  • 4. Great divide also on activity – indicator for degree of engagement? #
of
Updates 
255 119 Avg
Dec
09 Avg
Jul
09 Source:
www.twi-er.com,
July
13th
and
Dec
31st
2009;
whdotpharma
analysis jeudi, 21 janvier 2010
  • 5. Boehringer and JNJ track above average in terms of engagement #
of
Following The twitter engagement quardrant: above average followers, following and updates! Average
following:
392 Average
Updates:
119 #
of
Updates Bubble
size
=
#
of
followers Source:
www.twi-er.com,
July
13th
and
Dec
31st
2009;
whdotpharma
analysis jeudi, 21 janvier 2010
  • 6. ... Roche and AstraZeneca moving into the “engagement“ quardrant #
of
Following @Pfizer_news Avrg
following:
600 @genentechnews Avrg
Updates:
255 #
of
Updates Avrg
Bubble
size
=
#
of
followers Source:
www.twi-er.com,
July
13th
and
Dec
31st
2009;
whdotpharma
analysis jeudi, 21 janvier 2010
  • 7. 26% of Boehringer followers are large accounts (>500 followers) vs. only 14% for Novartis - less is more? Number of % with >500 followers followers 3 941 15% 3 865 14% 3 304 26% 2 780 20% 2 574 20% Avrg 19% Number of followers that are followed by 19% of pharma followers (roughly 3000 accounts) are large accounts (>500 followers). The segmentation and profiling of these accounts, will be the basis of Part II of this analysis. Source:
www.twi-er.com,
Dec
31st
2009;
whdotpharma
analysis jeudi, 21 janvier 2010
  • 8. Coming to whydotpharma soon: the mapping of the pharma twittersphere! Stay tuned! jeudi, 21 janvier 2010